Patient Stratification
"Digistain has shown statistically significant prognostic ability for HR-positive HER2-negative primary operable breast cancer by accurately stratifying patients into high and low risk. With currently over-burdened healthcare systems and the need to improve global cancer care inequalities, the ability to provide low-cost, rapid, and widely accessible prognostic testing suggests that Digistain may have the potential for significant clinical utility".
Professor Charles Coombes, FMedSciDirector of The Imperial CRUK Cancer Centre "Digistain has shown statistically significant prognostic ability for HR-positive HER2-negative primary operable breast cancer by accurately stratifying patients into high and low risk. With currently over-burdened healthcare systems and the need to improve global cancer care inequalities, the ability to provide low-cost, rapid, and widely accessible prognostic testing suggests that Digistain may have the potential for significant clinical utility".
Cost Effectiveness
"It gives the same information about the need for chemotherapy at almost one-fourth the current costs. The new invention can help patients who have been detected with early stage breast cancer and only a few women benefit from chemotherapy at this stage."
Manish Singhal MD, DM(AIIMS)Senior Consultant Medical Oncology at Apollo Hospitals "It gives the same information about the need for chemotherapy at almost one-fourth the current costs. The new invention can help patients who have been detected with early stage breast cancer and only a few women benefit from chemotherapy at this stage."
Proteomic Approach
“When clinicopathological factors are augmented with objective assessment of grading, risk evaluation consistency outperforms genomic risk prediction.”
Professor William Dooley, MD FACSProfessor of Surgical Oncology, Johns Hopkins University “When clinicopathological factors are augmented with objective assessment of grading, risk evaluation consistency outperforms genomic risk prediction.”
Decision Guidance
"Digistain risk of recurrence assessment is pivotal in choosing the optimal treatment for each of my patients, geared towards improving their survival"
Dr María José MuñozClinical Oncologist, SOLCA-Quito "Digistain risk of recurrence assessment is pivotal in choosing the optimal treatment for each of my patients, geared towards improving their survival"
Clinically Validated
“Typical prognostic factors such as the NPI (the gold standard used across the world) have a hazard ratio of around 2. A hazard ratio >4 is excellent. Digistain® appears to be a much better classifier of risk than other biomarkers I’ve seen used in clinics today”
Prof Andrew Green Ian Ellis’s Group Nottingham University “Typical prognostic factors such as the NPI (the gold standard used across the world) have a hazard ratio of around 2. A hazard ratio >4 is excellent. Digistain® appears to be a much better classifier of risk than other biomarkers I’ve seen used in clinics today”
Individualised Treatment Approach
“Digistain is a valuable tool for determining the precise adjuvant therapy that my breast cancer patients will benefit from. When results point towards chemotherapy as the optimal course of action for reducing risk of recurrence, patient feels more confident and open towards it.”
Dr Jose CastilloClinical Oncologist, SOLCA-Quito “Digistain is a valuable tool for determining the precise adjuvant therapy that my breast cancer patients will benefit from. When results point towards chemotherapy as the optimal course of action for reducing risk of recurrence, patient feels more confident and open towards it.”
